All In Biotech

Drug Trial Radar · NCT06542731

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Phase 1 Study of ONO-4578 Given as Combinations of ONO-4578, ONO-4538, Docetaxel and Ramucirumab in Subjects With Metastatic Non-small Cell Lung Cancer Who Have Had Disease Progression During or After One Prior First-line Anti-PD-(L) 1 Antibody and Platinum-based Chemotherapy for Advanced/Metastatic Disease

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Jun 1, 2021

Primary completion

Oct 30, 2025

Study completion Oct 30, 2025

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is PhaseⅠstudy to evaluate the tolerability and safety of ONO-4578 and ONO-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanced or recurrent NSCLC who were refractory to a combination therapy containing an anti-PD-(L)1 antibody and a platinum-based drug

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • ONO-4578Drug

    Specified dose on specified days

  • ONO-4538Drug

    Specified dose on specified days

  • DocetaxelDrug

    Specified dose on specified days

  • RamucirumabDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities(DLT)Time frame: 21 days
  2. Adverse event(AE)Time frame: Up to 28 days after the last dose

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Juntendo University Hospital

    Bunkyō City, Japan

  • Japan Anti-Tuberculosis Association Fukujuji Hospital

    Kiyose-shi, Japan

  • The Cancer Institute Hospital of JFCR

    Kōtoku, Japan

  • Niigata Cancer Center Hospital

    Niigata, Japan

  • Hyogo Medical University Hospital

    Nishinomiya-shi, Japan

  • Osaka Prefectural Hospital Organization Osaka International Cancer Institute

    Osaka, Japan

  • Kitasato University Hospital

    Sagamihara-shi, Japan

  • National Hospital Organization Kinki-Chuo Chest Medical Center

    Sakai, Japan

  • Teikyo University Hospital

    tabashi City, Japan

  • Osaka Medical and Pharmaceutical University Hospital

    Takatsuki-shi, Japan

  • Kanagawa Cancer Center

    Yokohama, Japan

  • Saitama Cancer Center

    Shinden, Saitama, Japan

  • National Cancer Center Hospital

    Chuo Ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.